ஜர்னல் ஆஃப் பாக்டீரியாலஜி & பாராசிட்டாலஜி

சுருக்கம்

A Follow up Study of Bacteriology and Antibiotic Sensitivity Pattern of Urinary Tract Infection in a Tertiary Care Hospital in Bangladesh

MI Majumder1*, T Ahmed2, N Sakib3, AR Khan4 and CK Saha5

Background: Urinary tract infections (UTIs) are a common infection. The aim of this follow up study is to see the changing trends in bacteriology and antibiotic sensitivity pattern among uropathogens in comparison to similar study 5 years back.
Materials and methods: We performed a prospective study in Comilla medical college hospital, Bangladesh during the period of July 2015-June 2016. Urine samples from 658 suspected UTI patients aged above 12 years inoculated for semiquantitative urine culture and sensitivity test. Antibiotic susceptibility pattern was done by Kirby- Bauer disc diffusion method following clinical laboratory science (CLS) program.
Results: Culture passivity were in 198 samples among 658 inoculated samples. E. coli was isolated from 171(86%) samples which was the most predominant bacteria followed by Klebsiella and Enterococcus. UTI with E. coli was significantly increased in the year 2016 in comparison to 2011. Meropenem, imipenem, amikacin, tazobactum, gentamycin nitrofurantoin, and mecillinum, found sensitive against 88% to100% of the uropathogens. Bacteria offered high degree of resistance against commonly used antibiotics-amoxycillin, amoxiclav, cephradine and cefixime ranging 60% to 86%. Comparative study of 2016 vs. 2011 shows significant reduction in sensitivity for imipenum, ceftriaxone, amoxiclav and increased sensitivity for nalidexic acid, ciprofloxacin, mecillinum, colistin, cotrimoxazole.
Conclusion: UTI with E. coli was significantly increased in the year 2016. This study failed to show a steady increase in resistance to all studied antibiotics. Imipenem, meropenem, tazobactum, amikacin and nitrofurantoin still remain more sensitive in this comparative study. Comparative study of 2016 vs. 2011 shows significant increasing resistance for imipenum, ceftriaxone, amoxiclav and increasing sensitivity for nalidexic acid, ciprofloxacin, mecillinum, colistin, cotrimoxazole.